Clinical trials: Lipid Disorders
Type 2 Diabetes Mellitus, Cardiovascular Disease
Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease
The purpose of this study is to evaluate the Efficacy and Safety of Dehypotin® in the Patients with Type 2 Diabetes Mellitus or Cardiovascular Disease.
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- NCT01108978
- Testing
- Dehypotin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
Metabolic Syndrome
Regional Observation of the Metabolic Syndrome
The aim of the study, is to assess the prevalence of metabolic syndrome in Italy on a regional basis, defined according to National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) guidelines criteria.
- Trial name
- ORSA (NCT00874952)
- Where
- Italy
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Dyslipidemia
MK0524A Bioequivalence Study (0524A-059)
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.
- Trial name
- NCT00944645
- Testing
- niacin (+) laropiprant (Source 1), Comparator: niacin (+) laropiprant (Source 2)
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye Disease
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT06323395
- Testing
- Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops
- Where
- 2 sites in Serbia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Hypercholesterolemia
Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels
The aim of this study is to assess the safety and tolerability of varying dose and load regimens of ISIS 301012 in people who have elevated LDL-cholesterol levels.
- Trial name
- NCT00216463
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Kastle Therapeutics, LLC
Dyslipidemia, Carotid Atherosclerotic Plaques
Yangxin Dawayimixike Honey Paste for Carotid Atherosclerotic Plaque With Dyslipidemia: A Randomized Controlled Clinical Study
This clinical trial aims to evaluate the efficacy and safety of Yangxin Dawayimixike Honey Paste in intervening carotid atherosclerotic plaque combined with dyslipidemia.
- Trial name
- NCT07314775
- Testing
- Yangxin Dawayimixike Honey Paste
- Volunteers
- 422 people
- Sponsor
- Xinjiang Uygur Pharmaceutical Co., Ltd.
Hyperlipidemias
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.
- Trial name
- NCT02719028
- Testing
- Antroquinonol
- Where
- 6 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Golden Biotechnology Corporation
Dyslipidemias
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or…
- Trial name
- NCT02977065
- Testing
- Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemias
Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea
A Cohort Study for Comparison of Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration and Statin Prescription Patterns in Patients With Dyslipidemia in Korea.
- Trial name
- NCT04829149
- Testing
- Observational
- Where
- South Korea
- Volunteers
- 5,717 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Dyslipidemias
Study of ARO-APOC3 in Adults With Dyslipidemia
This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility…
- Trial name
- NCT05413135
- Testing
- ARO-APOC3
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 418 people
- Sponsor
- Arrowhead Pharmaceuticals
HbA1c Level Associated With Lipid Compositions
to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting…
- Trial name
- SIPHON (NCT02056847)
- Testing
- Pitavastatin calcium 4mg, Pitavastatin calcium 2mg
- Where
- South Korea
- Volunteers
- 313 people
- Sponsor
- JW Pharmaceutical
Dyslipidemia Associated With Type II Diabetes Mellitus
Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.
Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2…
- Trial name
- NCT04882293
- Testing
- Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, Atorvastatin (Lipitor ®)
- Where
- Mexico
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Healthy Participants
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995
- Trial name
- NCT06517914
- Testing
- YH35995
- Where
- South Korea
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Severe Hypertriglyceridemia
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
This is a randomized, open-label crossover study. The primary objective of this study is to compare the relative bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and the…
- Trial name
- ECLIPSEIV (NCT02189252)
- Testing
- Epanova, Lovaza
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Fabry Disease
French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat
This is a noninterventional cohort study to evaluate the effects of migalastat, on long-term safety, effectiveness, and quality of life (QOL) in patients with Fabry disease.
- Trial name
- NCT04602364
- Testing
- Noninterventional
- Where
- 13 sites in France
- Volunteers
- 48 people
- Sponsor
- Amicus Therapeutics France SAS
Dyslipidemias
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take…
- Trial name
- VINCENT (NCT06496243)
- Testing
- obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- NewAmsterdam Pharma
Fed
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex® 5 mg tablet in healthy subjects under fed conditions.
- Trial name
- NCT01314352
- Testing
- Desloratadine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Hypercholesterolemia
Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia
The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to…
- Trial name
- NCT00654407
- Testing
- Rosuvastatin, Atorvastatin, Simvastatin
- Volunteers
- 4,875 people
- Sponsor
- AstraZeneca
Farber's Lipogranulomatosis, Ceramidase Deficiency
Biomarker for Farber Disease (BioFarber)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood
- Conditions
- Farber's Lipogranulomatosis, Ceramidase Deficiency, Hepatomegaly, Splenomegaly
- Trial name
- BioFarber (NCT02298634)
- Where
- 3 sites in Egypt, Germany and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Vascular Diseases, Hypercholesterolemia
The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus
Double-blind, randomised, placebo-controlled, parallel group study with two intervention arms. The study will be conducted in 150 subjects and the primary objective is to show a fasting LDL-cholesterol and triglyceride lowering…
- Conditions
- Vascular Diseases, Hypercholesterolemia, Diabetes Mellitus
- Trial name
- NCT02288585
- Testing
- Plant sterols
- Where
- 2 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.